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Background: Coronavirus disease 2019 (COVID-19) caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing 
global health crisis that has caused large scale morbidity and 
mortality. We aimed to determine the exposure to SARS-CoV-2 among 
young children and healthcare workers by measurement of anti-S1 
antigen (spike protein) specific immunoglobulin G (IgG) using an in-
house optimized indirect enzyme-linked immunosorbent assay (ELISA) 
method. 
Methods: Plasma samples were collected from cohorts of healthcare 
workers (n = 287) and young children aged from 6 weeks to 2 years 
old (n = 150) pre-COVID-19 pandemic between September 2018 and 
November 2019 and post-COVID-19 pandemic between August and 
December 2020 were simultaneously tested for anti-SARS-CoV-2 S1 
specific IgG. The arithmetic mean of natural logarithm-transformed 
ELISA relative absorbance reading + (3 x standard deviation) of pre-
pandemic plasma was used as the cut-off to determine SARS-CoV-2 
IgG seropositivity of post-pandemic plasma. 
Results: There was no reactivity to SARS-CoV-2 S1 antigen detected in 
pre-pandemic plasma but in post pandemic plasma an 8.0% (23/287) 
IgG seropositivity in healthcare workers’ and 6.0% (9/150) 
seropositivity in children aged 2 years old was detected. 
Conclusions: Comparable levels of SARS-CoV-2 IgG seropositivity in 
healthcare workers and children suggest widespread exposure to 
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SARS-CoV-2 in Zambia during the first wave of the pandemic. This 
finding has implications for continued acquisition and transmission of 
infection in the healthcare setting, household, and wider community.
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Introduction
Coronavirus disease 2019 (COVID-19) caused by the novel 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
is an ongoing global public health emergency that as of April 
2021 has infected more than 100 million people and claimed 
nearly three million lives worldwide1. While reported incidence 
and mortality has been strikingly lower in Africa compared 
to other regions of the world, Africa within this period had still 
recorded over three million cases with over 70,000 deaths1. 
In Zambia, the first confirmed case of SARS-CoV-2 was 
reported on 18th March, 2020 and since then, over 90,000 
confirmed cases and more than 1,200 deaths have been 
reported as of April 20212,3. The robust global response to the 
pandemic has seen unprecedented advancements in research 
leading to elucidation of the SARS-CoV-2 genome4, devel-
opment of diagnostic tests and the accelerated development 
of vaccines in <12 months since the SARS-CoV-2 outbreak 
was first reported5,6 with more than 600 million vaccine doses 
administered by April 20211.
Nucleic acid-based testing is the current diagnostic test of 
choice for active SARS-CoV-2 infection but high costs and the 
need for specific sample collection and transport conditions, 
specialised laboratory facilities and skilled personnel limit 
accessibility and feasibility for large scale screening. In the 
absence of mass SARS-CoV-2 nucleic acid testing for disease 
surveillance particularly in lower income settings, the true 
extent of SARS-CoV-2 exposure within high-risk populations 
such as frontline healthcare workers and the wider population 
may be underestimated. In such settings, serology can serve as 
an important complementary diagnostic and surveillance tool7,8. 
Locally developed serological tests like the antibody-based 
immunoassays capable of effectively discriminating SARS-
CoV-2 exposure by detection of specific immunoglobulins9,10 are 
important for both immunosurveillance8 and evaluating vaccine 
responses post implementation.
An intriguing observation during the ongoing pandemic apart 
from the observed lower incidence and mortality rates in Africa 
was that the paediatric population recorded lower SARS-CoV-2 
incidence, severity and mortality compared to older age groups, 
a phenomenon also seen in Zambia11,12. Although representing 
only a small fraction of confirmed COVID-19 cases, children 
are susceptible to SARS-CoV-2 infection with a substantial 
proportion of infected children tending to be asymptomatic 
and potentially missed in symptom-based case detection 
strategies13. Children have mild disease that delays detection and 
can exhibit prolonged SARS-CoV-2 viral shedding regardless 
of symptomatology14. Children could therefore act as a hidden 
infectious reservoir for household and community transmission 
networks and thus, it is important to understand the epidemiology 
of SARS-CoV-2 infection in this population.
Our objectives were to develop and optimize an in-house 
semi quantitative, indirect enzyme-linked immunosorbent 
assay (ELISA) for immunoglobulin G (IgG) directed against 
SARS-CoV-2 spike glycoprotein (S1) and screen stored 
plasma samples from a cohort of healthcare workers and young 
children to permit estimation of SARS-CoV-2 seroprevalence 
within the healthcare setting and among young children 
residing in a peri urban community in Zambia.
Methods
Ethical considerations
This study protocol including a request for waiver of partici-
pant informed consent to utilize samples collected from exist-
ing studies was approved by the National Health Research 
Authority based on the existing participant informed consent 
and ethical clearance by the University of Zambia Biomedical 
Research Ethics Committee (UNZABREC) for the Hepatitis 
B vaccine study (UNZABREC Reference Number 003-01-19) 
and rotavirus vaccine trial (UNZABREC Reference Number 
003-02-18).
Study setting and participants
This study included healthcare workers that were enrolled in 
an existing “before and after” interventional study aimed at 
demonstrating healthcare worker’s protection against Hepatitis 
B infection by vaccination15. The Hepatitis B vaccine study was 
conducted in Kalulushi district on the Copperbelt province of 
Zambia having a projected total population of approximately 
140,000 in 201916. Kalulushi district has nine health posts, 
eleven clinics and one second level hospital as well as one nurs-
ing school, one health training institute and university. The 
district had an estimated 405 healthcare workers with an addi-
tional 407 students and lecturers in health training institutions 
(Data sourced from Kalulushi District Health Office, 2019). 
The sample size for the Hepatitis B vaccine study was cal-
culated based on confidence interval for one proportion and 
required a minimum sample size of 513 healthcare workers 
to estimate the prevalence of Hepatitis B with a 95% confi-
dence interval and 5% width interval assuming a prevalence of 
8.6%17,18. The sample size was adjusted by 25% to control for 
losses to follow-up and secondary analyses. Before enrol-
ment, sensitization talks about the Hepatitis B vaccine study 
were conducted by the study team at the health facilities and 
health professional schools after which eligibility was deter-
mined and written informed consent sought from those 
healthcare workers that were willing to participate. Inclusion 
criteria for the healthcare workers were individuals formally 
employed within a public health facility or students enrolled 
at an allied healthcare training institution in the district, aged 
≥18 years and willing to consent and meet study training and 
follow up requirements. Refusal to consent, pregnancy, yeast 
allergy, hypersensitivity, acute febrile illness and receipt of 
steroids, immune modulators or blood products were exclusion-
ary criteria. A total of 641 healthcare workers were recruited 
using this approach and the enrolled healthcare workers 
were followed up from November 2019 through August 2020.
Paediatric plasma samples included in this study were from 
an ongoing open label randomised controlled rotavirus vac-
cine trial comparing two versus three dose vaccination in 
Lusaka, Zambia19. The outcome of the rotavirus vaccine study 
was boosted antibody responses after administration of the 
third vaccine dose in the intervention arm. The study determined 
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the sample size based on an anticipated 15% or greater 
increase in rotavirus antibody response after the third dose and 
required a total of 196 infants (98 infants per arm) to detect 
this boosted response at an 80% power using two-sample 
t-test, and assuming equal standard deviation at 5% level of 
significance. A 10% upward sample size adjustment was 
made to account for losses in follow up to reach a total of 214 
children that were enrolled from a population residing in “George 
compound”, a peri-urban unplanned settlement in Lusaka. 
Children aged between 6 to 12 weeks old attending the George 
public health facility with their mothers were targeted for 
enrolment. Mother-child pairs were approached during their 
visit to the maternal and child health department by the study 
Research Nurse and provided with sensitization information 
about the study in the mother’s local language of choice. Moth-
ers that were interested were invited to the study research unit 
co-located within the health facility premises for more detailed 
information during which willing mothers were checked for 
eligibility and taken through the written informed consent 
process. Criteria for enrolment included the mothers’ willingness 
to participate voluntarily and provide consent, child’s’ eligibility 
for Rotarix vaccination as per national policy and mothers’ 
willingness for child to undergo defined study procedures 
and residence in the study area for the duration of the study. 
Contraindication to rotavirus vaccination, previous receipt of 
rotavirus vaccine, recent immunosuppressive therapy includ-
ing high-dose systemic corticosteroids, history of receiving 
blood transfusion or blood products, including immunoglobu-
lins within the previous 6 months, any condition deemed by 
the study investigator to pose potential harm to the child or 
jeopardize the validity of study result and any existing congeni-
tal anomalies constituted exclusionary criteria. Eligible, con-
senting mothers were enrolled and followed up until the child 
attained 2 years of age.
Data collection
From the enrolled healthcare workers under the Hepatitis 
B vaccine study, demographic data and pre-vaccination plasma 
samples were collected at baseline after written informed con-
sent was obtained. Additional plasma samples were collected 
at subsequent scheduled appointments after vaccination during 
the follow-up period. In our study we utilized the health-
care worker pre-vaccination baseline plasma collected prior to 
declaration of the COVID-19 pandemic between November 
and December 2019 and the matched post-vaccination plasma 
samples that were collected in August 2020 during the 
COVID-19 pandemic.
Similarly, in the rotavirus vaccine trial mother-child cohort, 
demographic data and pre-vaccination plasma was collected 
at enrolment after mother’s written informed consent was 
obtained. During the follow up period, additional plasma sam-
ples from the children were collected post-vaccination during 
scheduled study clinic appointments. For the present study, we 
used pre-vaccination baseline plasma collected when children 
were aged 6 to 12 weeks old between September and November 
2018 (pre-COVID-19 pandemic) and matched plasma collected 
in the follow up period between August and December 
2020 during the COVID-19 pandemic when children were 
aged 2 years old. Plasma samples from both cohorts were 
stored at -20°C prior to serological testing in this study.
Laboratory procedures
Set up and optimisation of in-house ELISA. To develop our 
SARS-CoV-2 ELISA, we tested sero-reactivity of plasma 
against commercially available SARS-CoV-2 Spike/S1-His 
recombinant protein (Cat 40591-V08H, Sino Biologicals, China) 
using an indirect ELISA procedure. Seropositive plasma con-
trols for anti-SARS-CoV-2 IgG were selected from known 
convalescent local Zambian adults previously tested and con-
firmed to be SARS-CoV-2 positive by polymerase chain reaction. 
Prospective adult donors were approached by the study team 
with information about the study and a request for plasma sam-
ples. Plasma was obtained from five individuals that were 
willing and provided consent to have a blood sample drawn. In 
addition to these seropositive controls, pre-pandemic plasma 
from five mothers among the mother-child cohort were used 
as seronegative plasma controls during initial experiments.
In these initial experiments we tested individual and pooled sero-
positive and seronegative control plasma including a blank (1% 
skim milk in phosphate buffer, Blotto) control in the indirect 
ELISA assay method. To optimise the assay, we tested vary-
ing antigen coating concentrations, plasma sample dilutions, 
detection antibody concentrations, assay blocking solution 
and test sample incubation conditions. Briefly, microtiter plate 
wells were incubated with 50μL SARS-CoV-2 S1 antigen 
at three different concentrations (0.5μg/ml, 1μg/ml and 
2μg/ml) and blocked with different volumes of blotto (150μL 
or 200μL) for three hours at room temperature. Plasma sam-
ple controls at different dilutions (1:40 through 1:6400) and 
blotto (as blank to control for background absorbance) were 
then added in duplicate wells and incubated for either 2 hours 
at 37°C or overnight at 4°C. Peroxidase-conjugated anti-human 
IgG detection antibody at two dilutions (1:10000 or 1:15000) 
was added to the wells before incubation for three hours at 
room temperature, followed by addition of substrate, colour 
development and absorbance optical density (OD) reading at 
492nm. Prior to each incubation step, the plate was placed on 
an incubator shaker set at 20°C, 270 revolutions per minute 
for 20 minutes. Plate was also washed in between assay rea-
gent and sample addition steps. We set our optimized ELISA 
as the assay with parameters yielding a >1.5 absorbance OD 
reading value for the pooled seropositive plasma and a 3-fold 
or more lower OD value for the seronegative control and blank. 
Based on these experiments, our optimized indirect ELISA 
required 1μg/ml antigen coating concentration, 200μL blocking 
buffer volume, 1:100 sample dilution and overnight incubation 
and 1:15000 peroxidase-conjugated anti-human IgG antibody 
dilution. The optimisation experiments additionally determined 
a donor positive control sample with the highest SARS-CoV-2 
IgG titer which was assigned as an in-house standard. These 
optimized conditions and procedures were used in all the 
subsequent assays.
Determination of SARS-CoV-2 IgG antibodies by ELISA. 
Healthcare workers’ and children’s plasma samples were tested 
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using the optimized indirect ELISA. Briefly, a 50μL volume 
of 1μg/ml SARS-CoV-2 antigen concentration in sodium car-
bonate-bicarbonate coating buffer at pH 9.6±0.2 was added to 
the microtiter plate wells (Ref 655061, Greiner Bio-One) and 
incubated overnight at 4°C. The following day, the plate was 
blocked with 200μL 1% blotto, weight/volume skim milk in 
phosphate-buffered saline containing 0.25% volume/volume 
Tween20 (Cat P1379, Sigma-Aldrich) (PBST), and incubated 
at room temperature for 3 hours. A 5μL volume of pre- and 
post-pandemic matched plasma sample diluted in a two-step wise 
manner in PBST and blotto to a final 1:100 was added in dupli-
cate wells and incubated at 4°C overnight. On the third day, 
the plate was incubated with 50μL of peroxidase-conjugated goat 
anti-human IgG (Cat A0170, Sigma-Aldrich) diluted 1:15000 
in PBST for 3 hours at room temperature. The colour reac-
tion was developed using 50μL o-Phenylenediamine dihydro-
chloride substrate (Cat P4664, Sigma-Aldrich) diluted in citric 
acid phosphate buffer containing 0.03% volume/volume 30% 
hydrogen peroxide and stopped by addition of 100μL 1M 
Sulphuric acid before reading absorbance optical density (OD) 
at 492nm. Throughout the assay, wells were washed five times 
with PBST in between the ELISA steps. In each experiment, 
eight two-fold dilutions (1:100 to 1:12800) of the in-house 
SARS-CoV-2 IgG standard plasma, pooled seropositive and 
seronegative control plasma and blank (blotto) were included 
in duplicate wells. The pre-pandemic plasma samples were 
treated as internal negative controls to the matched post-pandemic 
samples for each participant in both the study cohorts.
Statistical analysis
Key background characteristics of healthcare workers and chil-
dren were summarised using frequency and percentage for 
categorical variables, whereas median and interquartile range 
(IQR) were used to summarise age. Absorbance levels were 
calculated for each assay plate as relative absorbance units (rAU) 
with reference to values obtained for an in-house, high-titer 
standard plasma (assigned a value of 1000 rAU). To define sero-
positivity for SARS-CoV-2 IgG, we calculated a cut-off as 
the arithmetic mean of natural logarithm-transformed mean 
blank corrected arbitrary rAU of all pre-pandemic samples tested 
+ (3 x standard deviation of the natural logarithm-transformed 
mean blank corrected arbitrary rAU). Seroprevalence was 
calculated as the proportion of samples with natural-log- arbi-
trary rAU above the calculated cut-off for the respective cohort. 
Fisher’s exact test was used to assess the association of sero-
prevalence and key background characteristics. Dot plots and 
range plots were used to characterise the arbitrary rAU of sam-
ples in the two periods (pre- and post-SARS-CoV-2 pandemic). 
All analyses were performed using Stata 16 MP4 (StataCorp, 
College Station, TX, USA).
Results
A total of 287 healthcare workers were included in this study 
and had their pre- and post-pandemic matched plasma tested 
(Figure 1)20. Included healthcare workers had a median age 
of 29 years (interquartile range 25, 37), were mostly female 
187/287 (65.2%), had normal body mass index 149/287 (51.9%) 
and were unmarried 145/287 (50.5%). Among these health-
care workers most were medical staff 131/287 (45.6%), while 
100/287 (34.8%) were support staff and 53/287 (18.5%) were 
students.
A cut-off of 5.5381 arbitrary rAU was calculated from the 
healthcare worker pre-pandemic plasma and was used to 
Figure 1. Selection of healthcare worker and child plasma samples included in the study. The study included stored matched 
plasma samples collected before the coronavirus disease 2019 (COVID-19) pandemic between September 2018 and December 2019 and 
post-pandemic between August and December 2020 from a cohort of healthcare workers (n = 287) recruited under a Hepatitis B vaccine 
study and children (n = 150) recruited under a rotavirus vaccine clinical
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determine seropositivity for this cohort. Overall, 23/287 health-
care workers were reactive for SARS-CoV-2 IgG above the 
calculated cut-off giving 8.0% seropositivity. Among these 
seropositives, most were among medical staff particularly among 
Nurses and Mid-wives. We did not find an association between 
any background characteristic included and seropositivity 
for SARS-CoV-2 IgG (Table 1).
We included and tested pre- and post-pandemic plasma 
from a total of 150 children in this study (Figure 1). These 
children had a median age of 6 weeks (interquartile range 6,6), 
were mostly male 84/150 (56%) and HIV unexposed 103/287 
(68.7%). Majority of the children were from mothers that were 
married 123/287 (82%), unemployed 108/287 (72%) with 
some primary level of education 88/287 (58.7%) and from 
households comprising up to three children 88/287 (58.7%).
We calculated a cut-off of 4.7508 arbitrary rAU from pre-pan-
demic plasma of this cohort and detected 9/150 children aged 
2 years old that were reactive for SARS-CoV-2 IgG above this 
cut-off giving a 6.0% seropositivity in this cohort compara-
ble to the adult healthcare worker cohort. We found no associa-
tion between background characteristics and SARS-CoV-2 IgG 
seropositivity (Table 2).
Table 1. Severe acute respiratory syndrome coronavirus 2 immunoglobulin G (SARS-CoV-2 
IgG) seropositivity among healthcare workers by background characteristics.
Characteristics
# of healthcare 





Age (years): median (IQR) 29 (25, 37)
    18–25 81 (28.2) 3 (3.7)
0.132
    26–35 126 (43.9) 11 (8.7)
    36–45 45 (15.7) 7 (15.6)
    45+ 35 (12.2) 2 (5.7)
Sex
    Female 187 (65.2) 17 (9.1)
0.494
    Male 100 (34.8) 6 (6.0)
Body mass index (kg/m2)
    Underweight 17 (5.9) 0 (0)
0.192
    Normal 149 (51.9) 10 (6.7)
    Overweight 114 (39.7) 13 (11.4)
    Missing 7 (2.4)
Marital status
    Single 145 (50.5) 11 (7.6)
0.647
    Married 126 (43.9) 12 (9.5)
    Divorced/separated/ widowed 13 (4.5) 0 (0)
    Missing 3 (1.1)
HCW category
    Medical staff 
    Of these: 
    - Nurse/Mid-wife 
    - Lab Tech/Scientist 















    Support staff 100 (34.8) 7 (7.0)
    Student 53 (18.5) 4 (7.6)
    Missing 3 (1.1) 1 (33.3)
Total 287 (100) 23 (8.0)
1Other medical staff include Clinical officers, Pharmacists, Anaesthetists, Dentists, Ophthalmologists, Public 
Health Officers and Environmental Health Scientists 
Page 6 of 14
Wellcome Open Research 2021, 6:97 Last updated: 09 JUL 2021
Significantly (p<0.001) higher mean arbitrary rAU was observed 
in post-pandemic plasma compared to pre-pandemic plasma 
in both healthcare workers and children (Figure 2).
Among the 23 SARS-CoV-2 IgG seropositives from the health-
care worker and 9 seropositives from the children cohort, we 
observed a significant difference in arbitrary rAU absorbance 
readings between pre- and post-pandemic plasma (Figure 3).
Discussion
We report comparable seroprevalence for SARS-CoV-2 S1 anti-
gen in very young Zambian children and healthcare workers 
using a locally developed and optimized indirect ELISA assay. 
Direct comparison of pre- and post-pandemic plasma from the 
same individuals permits accurate evaluation of exposure to 
SARS-CoV-2 and avoids contaminating cross-reactive responses 
to other circulating human coronaviruses (hCoVs). Using an 
immunofluorescence assay, a recent analysis of pre-pandemic 
sera cohorts from sub–Saharan Africa estimated seropreva-
lence of up to 17.1% for SARS-CoV-2 nucleocapsid and up to 
4% for spike trimer21. Up to 5% reactivity in pre-pandemic sera 
against spike S2 antigen was observed in SARS-CoV-2 unex-
posed UK individuals whereas no reactivity was detected 
against S1 antigen using a flow cytometry-based assay22. The 
Table 2. Severe acute respiratory syndrome coronavirus 2 immunoglobulin 
G (SARS-CoV-2 IgG) seropositivity in children aged 2 years old by background 
characteristics.
Characteristics






Age (weeks): median (IQR) 6 (6,6)
    5 26 (17.3) 2 (7.7)
0.861
    6 108 (72.0) 6 (5.6)
    7+ 16 (10.7) 1 (6.3)
Sex
    Male 84 (56.0) 7 (8.3)
0.299
    Female 66 (44.0) 2 (3.0)
HIV exposure
    Unexposed 103 (68.7) 6 (5.8)
1.000
    Exposed 47 (31.3) 3 (6.4)
Mother’s marital status
    Married 123 (82.0) 5 (4.1)
0.057
    Single 27 (18.0) 4 (14.8)
Mother’s employment status
    Unemployed 108 (72.0) 7 (6.5)
1.000
    Employed 42 (28.0) 2 (4.7)
Mother’s educationallevel 
    None 34 (22.7) 1 (2.9)
0.798    Primary 88 (58.7) 6 (6.8)
    Secondary 28 (18.7) 2 (7.1)
Number of children in the 
household
1–3 88 (58.7) 3 (3.4)
0.1944–6 55 (36.7) 6 (10.9)
7+ 7 (4.7) 0 (0)
Total 150 (100) 9 (6.0)
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Figure 2. Distribution of natural-logarithm arbitrary relative absorbance units (rAU) pre-post COVID-19 pandemic period among healthcare 
workers (A) and children (B). The mean  log-arbitrary  rAU and 95% confidence  intervals are shown as  range plots  for  the pre and post 
coronavirus disease 2019 (COVID-19) pandemic plasma for the healthcare workers (n = 287) and children (n = 150). The student t-test of 
equality of mean log-arbitrary rAU between the two periods for each cohort are shown. The red dashed line shows the calculated cut-off 
derived from the pre-pandemic samples of each cohort as the mean log-arbitrary rAU (+ 3 x standard deviations).
Figure 3. Distribution of natural log-arbitrary relative absorbance units (rAU) in the pre and post pandemic period among 
SARS-CoV-2 IgG seropositive children and healthcare workers. Pre-and post-pandemic plasma paired data points for arbitrary rAU are 
shown for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) seropositive healthcare workers (n = 23) 
and children (n = 9). 
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selection of spike S1 protein for detection of SARS-CoV-2 in 
our assay therefore permits a further level of control for 
avoiding detection of potentially cross-reactive antibody 
responses23,24. Further studies will assess the degree of expo-
sure to circulating coronaviruses including hCoV-NL63, hCoV-
229E, hCoV-0C43 and hCoV-HKU1 to address the potential 
contribution of cross-protective immunity in the wider popu-
lation. As circulating coronavirus infections are also acquired 
in early life25,26, the acquisition of SARS-CoV-2 infection 
in very young children will be of particular interest, providing 
a potential opportunity to examine immunity to SARS-CoV-2 
in children who are seronegative for circulating coronavirus 
strains.
The durability of anti-SARS-CoV-2 antibody responses also 
has important implications for estimates of seroprevalence and 
vaccine efficacy. Recent longitudinal studies have indicated 
significant and concerning decays in antibody responses to 
SARS-CoV-2 over time. Anti-nucleocapsid IgG titres were 
reported to decline by 50% within 3 months27,28. However, IgG 
against spike trimer can be stable for at least 6 months27. The 
detection of antibody to spike S1 protein in our study therefore 
provides further confidence of the accuracy of our seropreva-
lence estimates, the longest likely intervals between infection 
and plasma sampling in our cohorts being between 8 months 
for healthcare workers and 12 months for young children. 
Longitudinal follow up of SARS-CoV-2 IgG seropositives 
presented in this study will inform the durability of antibody 
responses to spike S1 antigen in the two very different cohorts 
presented here. African countries including Zambia have 
begun to roll out vaccinations among their populations, with 
>2,000 individuals vaccinated in Zambia as of 19th April 
202129. Serological assays such as the one presented here may 
prove useful in measuring longevity or waning of vaccine 
induced antibody responses and provide insights towards 
potential administration of booster doses.
At the beginning of August 2020, Zambia had recorded a 
cumulative 6,347 cases from a total of 85,560 tests conducted 
giving a 7.42% positivity rate, and cases continued rising to 
over 20,000 cases by December 202030,31. During this period, 
we found 8% seroprevalence among healthcare workers and 
6% seroprevalence among children within similar range 
to the country estimates. Our assay detects IgG responses 
which may be indicative of a previous and not an active 
SARS-CoV-2 infection and seropositive individuals in our 
study were at the time of sample collection non-hospitalised 
and otherwise asymptomatic, however, robust IgG responses 
can be detected as early as one week post exposure23. In any 
case, our results speak towards ongoing transmission within 
the healthcare setting and among very young children.
SARS-CoV-2 seropositivity among healthcare workers in 
Africa is variable across published reports which could be influ-
enced by variable testing methods, healthcare worker cohorts 
studied and SARS-CoV-2 epidemiology. While we have reported 
8% seroprevalence in healthcare workers using an in-house S1 
ELISA, commercially available ELISA tests showed a 45% 
seroprevalence in Nigeria based on spike S-trimer protein32 
while in Malawi this was 12.3%33 based on S2 and N protein. 
The N, S2 and whole spike protein-based assays may overesti-
mate exposure due to reported cross reactivity as opposed to the 
S1 antigen’s superiority in distinguishing SARS-CoV-2 expo-
sure. We found higher seropositivity among medical staff within 
the health facilities studied particularly among nurses and 
mid-wives. Reporting seroprevalence among healthcare work-
ers distinguished by role within health facilities is important 
to better target health facility-based infection prevention and 
control measures.
Children typically experience less severe outcomes from 
SARS-CoV-2 infection, yet the reason for this is unknown. 
Many hypotheses have been suggested among which include 
exposure to hCoVs that imparts pre-existing cross-protective 
immunity, non-specific protective effects of live vaccines, dif-
ferential distribution of and higher protective serum circulat-
ing angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 
receptor34,35. While the present study is limited in that we did 
not test for exposure and potential cross reactivity to seasonal 
hCoVs, our data has not shown any antibodies reactive to our 
ELISA target from pre-pandemic samples. Nonetheless, we 
have shown that post-pandemic, children are just as likely to get 
infected as adults and infections in children as young as 
2 years old are prevalent and have the potential to be transmitted 
widely within communities. These infections, being asympto-
matic have far reaching implications for transmissions within 
households and schools, and therefore the paediatric popu-
lation needs to be considered in large scale screening and 
immunosurveillance campaigns. In the very young chil-
dren like those included in our study, acquisition of infection 
from mothers is an important route of infection calling for the 
need to conduct research on transmission dynamics and con-
trol measures within mother-child cohorts. Additional research 
is also required to address unanswered questions on reasons 
for the lower disease severity in children.
Our study was limited in that our assay measured IgG which 
may not reflect active infection, utilized samples from 
another study which was not powered for this study’s aim and 
lacked comparison to available commercial tests. However, 
we are confident in our results as the pair of pre and post 
pandemic samples accounts for possible cross reactivity as a 
confounder, with the S1 antigen having little to no reported 
serological cross reactivity with other hCoVs. We tested a spe-
cific population of healthcare workers from a single district. 
The seroprevalence results may not be generalizable to the 
overall healthcare worker population across different types of 
health facilities and districts having different levels of catch-
ment population, infection control capacity and infrastructure. 
A larger and more representative sample and powered study 
may be required to accurately assess this. However, our data 
provides an estimate of seroprevalence in this specific group. 
We tested seroprevalence in children who were recruited 
under an ongoing trial and remained in follow-up. Children 
were enrolled as they randomly attended the health facility 
and therefore results could be generalizable in this specific age 
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group. However, differences in characteristics of children that 
remained in follow up as opposed to those who did not and 
were therefore not tested could potentially influence estimates 
and may limit this generalization.
Conclusions
Establishment of the SARS-CoV-2 antibody assay in-country 
has potential to create avenues for epidemiological immuno-
surveillance studies to determine SARS-CoV-2 exposure in the 
local communities and specific populations. In our study, we 
have shown that children’s exposure to SARS-CoV-2 infection 
is comparable to high-risk adults highlighting the importance 
of this paediatric population when considering infection control 
measures. Such significant exposure among very young chil-
dren should inform targeting households in addition to infec-
tion prevention and control measures being applied at health 
facility level.
Data availability
Figshare: Comparable exposure to SARS-CoV-2 in young 
children and healthcare workers in Zambia. https://doi.org/ 
10.6084/m9.figshare.14237285.v220.
This project contains the following underlying data:
• SARS_Data_Dictionery.pdf
• SARS Child dataset.csv
• SARS HCW dataset.csv
Data are available under the terms of the Creative Commons 
Attribution 4.0 International License (CC BY 4.0)
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This is an interesting paper which appears to have 3 objectives:
The development of an in-house elisa assay against the spike protein of SARS-CoV2 
 
1. 
The seroprevalence in healthcare workers 
 
2. 
The seroprevalence in children3. 
Each of these objectives could have stood independently and I feel the conflation of the three 
results in some confusion. 
 
With respect to the assay development, it is well-described. It would be improved, however, by a 
more rigorous evaluation (for example, comparison with a gold standard like PCR and with 
commercially available assays). 
 
The cohorts used were both convenient, but there is not description of possible symptomatology. 
 
It is unclear from both the introduction and the conclusion as to why socioeconomic status, 
marital status or BMI was included in the description. There are some significant omissions, 
including the absence of description of any symptoms. The healthcare worker cohort should be 
stratified according to degree of patient contact. The age of the children is unclear with respect to 
the blood draws and this should be clarified 
 
Figure 2 and 3 do not enhance the test and should be removed. 
 
This work utilises two existing cohorts – 1 paediatric (a rotavirus vaccine boost trial) and 1 adult 
(healthcare workers or students working in healthcare). These are interesting and potentially 
useful cohorts but I think they should be separated. With respect to the paediatric cohort, I have 
the following questions:
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Was the age reported the age at the first blood draw? If yes, how old were the children who 
were included with a second blood draw? 
 
1. 
Please justify the inclusion of maternal socioeconomic status. Is there any indication that 
the Zambian experience of SARS-CoV2 is affected by either educational or marital status 
 
2. 
Were there any symptoms reported by the mothers?3. 
For the healthcare worker:
Exposure differs amongst different categories of healthcare – please clarify what the “other 
healthcare workers” were, what the students were
1. 
The assay development is interesting. It would benefit, however, from comparison (if only in a 
subpopulation) with a commercially validated assay 
 
A logistic regression may be of use when comparing the different multiple factors rather than a 
Fishers exact test. The calculation of the relative absorption units is difficult to follow and may 
benefit from more thorough statistical review. Figure 2 and 3 are not helpful to the text. It is to be 
expected that more participants will test positive following the pandemic spread so comparing the 
pre- and post-pandemic relative absorption units and saying that they are higher after the 
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